ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 80 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $92,000 | +48.4% | 13,305 | +122.9% | 0.00% | – |
| Q2 2023 | $62,000 | +72.2% | 5,970 | +31.6% | 0.00% | – |
| Q1 2023 | $36,000 | -69.2% | 4,535 | -39.6% | 0.00% | – |
| Q4 2022 | $117,000 | +800.0% | 7,504 | +803.0% | 0.00% | – |
| Q3 2022 | $13,000 | +160.0% | 831 | +139.5% | 0.00% | – |
| Q2 2022 | $5,000 | -90.7% | 347 | -88.9% | 0.00% | – |
| Q1 2022 | $54,000 | -65.4% | 3,137 | -70.8% | 0.00% | – |
| Q4 2021 | $156,000 | +67.7% | 10,727 | +108.5% | 0.00% | – |
| Q3 2021 | $93,000 | +78.8% | 5,146 | +73.0% | 0.00% | – |
| Q2 2021 | $52,000 | -41.6% | 2,974 | -15.4% | 0.00% | – |
| Q1 2021 | $89,000 | +641.7% | 3,515 | +85.6% | 0.00% | – |
| Q4 2020 | $12,000 | +1100.0% | 1,894 | +406.4% | 0.00% | – |
| Q3 2020 | $1,000 | -85.7% | 374 | -91.5% | 0.00% | – |
| Q2 2020 | $7,000 | -12.5% | 4,409 | -44.6% | 0.00% | – |
| Q1 2020 | $8,000 | +14.3% | 7,964 | +99.2% | 0.00% | – |
| Q4 2019 | $7,000 | +600.0% | 3,998 | +519.8% | 0.00% | – |
| Q3 2019 | $1,000 | -87.5% | 645 | -82.3% | 0.00% | – |
| Q2 2019 | $8,000 | -72.4% | 3,645 | -25.7% | 0.00% | – |
| Q1 2019 | $29,000 | -21.6% | 4,906 | -1.8% | 0.00% | – |
| Q4 2018 | $37,000 | -63.7% | 4,995 | -29.2% | 0.00% | – |
| Q3 2018 | $102,000 | -22.7% | 7,054 | +6.8% | 0.00% | – |
| Q2 2018 | $132,000 | +15.8% | 6,602 | +1.3% | 0.00% | – |
| Q1 2018 | $114,000 | +375.0% | 6,517 | +561.0% | 0.00% | – |
| Q4 2017 | $24,000 | -57.9% | 986 | -55.3% | 0.00% | – |
| Q3 2017 | $57,000 | – | 2,205 | +15650.0% | 0.00% | – |
| Q2 2017 | $0 | -100.0% | 14 | -95.7% | 0.00% | – |
| Q1 2017 | $10,000 | -23.1% | 326 | -30.3% | 0.00% | – |
| Q4 2016 | $13,000 | – | 468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |